Burlington, CT, United States of America

Kevin Patrick Claffey

USPTO Granted Patents = 5 


Average Co-Inventor Count = 3.3

ph-index = 2

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2003-2022

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: **Kevin Patrick Claffey: Innovator in Antibody-Based Therapeutics**

Introduction

Kevin Patrick Claffey is a notable inventor based in Burlington, Connecticut, recognized for his significant contributions to the field of biotechnology. With a total of five patents to his name, Claffey has made remarkable advancements in the development of antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors.

Latest Patents

His latest patents focus on isolated antibodies or antigen-binding fragments that include specific heavy chain variable region sequences. These include three heavy chain complementary determining regions (HCDRs) with the following sequences: HCDR1 as GYRLSELS (SEQ ID NO: 1), HCDR2 as ISGWDGNT (SEQ ID NO: 2), and HCDR3 as ARASGYNY (SEQ ID NO: 3). The isolated antibodies specifically bind to human HSP90, particularly the HSP90 beta variant. These patents not only highlight the innovative compositions but also detail methods for their detection and therapeutic use.

Career Highlights

Throughout his career, Claffey has engaged in groundbreaking work while affiliated with prominent institutions such as the University of Connecticut and Beth Israel Deaconess Medical Center, Inc. His expertise and research focus have positioned him at the forefront of antibody development, making significant strides in therapeutic approaches for cancer treatment.

Collaborations

Claaffey has worked alongside esteemed colleagues including Timothy Hla and Teresa Sanchez, contributing to various projects aimed at improving the efficacy of cancer therapeutics. His collaborations reflect a commitment to advancing scientific knowledge and innovation through teamwork and shared expertise.

Conclusion

Kevin Patrick Claffey exemplifies the spirit of innovation in the field of biotechnology with his cutting-edge research and patent contributions. His developments in antibody-based therapies are paving the way for new treatment options in oncology, marking him as a key player in the ongoing fight against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…